Table 1.
Patients who underwent diagnostic deepening of the lesions detected with the fluorodeoxyglucose-positron emission tomography scan
| ID (n°) | Sex | Age | Primary disease | Side of BI | SUVmax | US | MMX | Lesion size (mm) | Histology or outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 77 | H-N | Left | 2.2 | Negative | Negative | 21 | IDC G2 |
| 2 | Female | 55 | Melanoma | Left | 3.2 | Negative | Negative | 23 | No biopsy |
| 3 | Female | 89 | Lung tumor | Left | 0.8 | Negative | Negative | 15 | No biopsy |
| 4 | Female | 81 | NHL | Left | 2.5 | Positive | Positive | 10 | Fullicular lymphoma |
| 5 | Female | 52 | NHL | Left | 2.2 | Negative | Negative | 28 | No biopsy |
| 6 | Female | 81 | Melanoma | Left | 0.7 | Positive | Positive | 11 | IDC G2 |
| 7 | Female | 82 | Lung tumor | Right | 2.1 | Positive | Positive | 7 | Adenoidocistic G3 |
| 8 | Female | 56 | Melanoma | Right | 0.8 | Negative | Negative | 12 | No biopsy |
| 9 | Female | 72 | Sarcoma | Left | 1.1 | Positive | Positive | 15 | Fibroadenoma |
| 10 | Female | 26 | HD | Left | 1.3 | Positive | 18 | Phylloid tumor | |
| 11 | Female | 54 | Lung tumor | Left | 1.4 | Positive | 10 | Fibroadenoma | |
| 12 | Female | 69 | Lung tumor | Left | 1.5 | Positive | Positive | 11 | Fibroadenoma |
| 13 | Female | 70 | Lung tumor | Right, left | 1.2 | Negative | Negative | 11 | No Biopsy |
| 14 | Female | 53 | Melanoma | Left | 15.7 | Positive | 12 | Carcinomatous mastitis | |
| 15 | Male | 40 | HD | Right | 0.8 | Positive | 12 | Hodgkin lymphoma | |
| 16 | Female | 90 | ThyrT | Left, right | 1.1 | Positive | 17 | IDC G2 | |
| 17 | Female | 70 | Vasculitis | Right | 3.9 | Positive | Positive | 18 | IDC G2 |
| 18 | Female | 72 | NHL | Left | 1.3 | Positive | Negative | 15 | IDC G2 |
| 19 | Female | 43 | Lung tumor | Right, left | 0.6 | Positive | 9 | Fibroadenoma | |
| 20 | Female | 79 | Lung tumor | Left | 0.9 | Positive | 17 | Fibroadenoma | |
| 21 | Female | 70 | TL | Right | 6.0 | Positive | 17 | T-Lymphoma | |
| 22 | Female | 65 | NHL | Right | 3.8 | Positive | 8 | Mantle cell Lymphoma | |
| 23 | Female | 42 | H-N | Left | 1.3 | Negative | Negative | 18 | No biopsy |
| 24 | Female | 78 | Lung tumor | Left, right | 1.2 | Positive | Positive | 8 | IDCG2 |
| 25 | Female | 67 | OC | Left | 1.1 | Negative | Negative | 17 | No biopsy |
| 26 | Male | 74 | NHL | Left | 2.5 | Positive | 23 | IDC G2 | |
| 27 | Female | 62 | Lung tumor | Left | 1.3 | Positive | Positive | 7 | IDC G2 |
| 28 | Female | 70 | NHL | Right | 1.5 | Positive | Positive | 9 | IDC G2 |
| 29 | Male | 73 | Lung tumor | Right | 1.8 | Negative | 12 | No biopsy | |
| 30 | Female | 67 | Lung tumor | Right, left | 2.5-1.8 | Positive | Positive | 25 | Fibroadenoma |
NHL: Non hodgkin lymphoma, HD: Hodgkin disease, ThyrT: Thyroid tumor, TL: T lymphoma, H-N: Head and neck tumor, OC: Occult cancer, US: Utra sound, MMX: Mammography, IDC: Infiltrating ductal carcinoma, BI: Breast incidentaloma, SUVmax: Standardized uptake value maximum